Axsome Therapeutics, Inc. (NASDAQ:AXSM) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) have received a consensus rating of “Moderate Buy” from the eighteen research firms that are currently covering the company, MarketBeat.com reports. Two analysts have rated the stock with a sell recommendation and sixteen have assigned a buy recommendation to the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $215.20.

Several equities analysts recently issued reports on the stock. Piper Sandler upped their price objective on shares of Axsome Therapeutics from $148.00 to $223.00 and gave the company an “overweight” rating in a research note on Friday, January 16th. Wells Fargo & Company boosted their price target on Axsome Therapeutics from $157.00 to $193.00 and gave the company an “overweight” rating in a report on Tuesday, January 13th. Weiss Ratings restated a “sell (d-)” rating on shares of Axsome Therapeutics in a report on Wednesday, January 21st. Royal Bank Of Canada lifted their price objective on Axsome Therapeutics from $212.00 to $219.00 and gave the company an “outperform” rating in a research report on Wednesday, January 21st. Finally, Mizuho set a $217.00 target price on Axsome Therapeutics in a research report on Wednesday, December 31st.

Insider Activity at Axsome Therapeutics

In other Axsome Therapeutics news, insider Ari Maizel sold 7,500 shares of the business’s stock in a transaction dated Wednesday, January 21st. The stock was sold at an average price of $184.44, for a total transaction of $1,383,300.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Herriot Tabuteau sold 78,703 shares of the stock in a transaction on Monday, January 5th. The shares were sold at an average price of $171.28, for a total value of $13,480,249.84. Following the completion of the sale, the chief executive officer owned 7,229 shares of the company’s stock, valued at approximately $1,238,183.12. This represents a 91.59% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 308,874 shares of company stock worth $51,390,805. 22.30% of the stock is owned by insiders.

Institutional Investors Weigh In On Axsome Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Versant Capital Management Inc lifted its holdings in Axsome Therapeutics by 20,300.0% in the 3rd quarter. Versant Capital Management Inc now owns 204 shares of the company’s stock worth $25,000 after buying an additional 203 shares in the last quarter. Kemnay Advisory Services Inc. acquired a new position in shares of Axsome Therapeutics in the fourth quarter worth about $31,000. First Horizon Corp purchased a new position in Axsome Therapeutics in the third quarter valued at about $34,000. Optiver Holding B.V. grew its stake in Axsome Therapeutics by 82.3% during the 3rd quarter. Optiver Holding B.V. now owns 288 shares of the company’s stock valued at $35,000 after purchasing an additional 130 shares in the last quarter. Finally, Ameriflex Group Inc. acquired a new stake in Axsome Therapeutics during the 4th quarter valued at approximately $37,000. Hedge funds and other institutional investors own 81.49% of the company’s stock.

Axsome Therapeutics Price Performance

Axsome Therapeutics stock opened at $184.74 on Thursday. The stock has a market capitalization of $9.31 billion, a P/E ratio of -39.56, a P/E/G ratio of 11.83 and a beta of 0.40. Axsome Therapeutics has a 12-month low of $86.99 and a 12-month high of $191.50. The company has a debt-to-equity ratio of 1.66, a current ratio of 1.57 and a quick ratio of 1.50. The firm’s 50-day moving average is $172.42 and its two-hundred day moving average is $143.04.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome’s pipeline includes several late-stage and approved product candidates.